Atai Life Sciences在其財務戰略中選擇比特幣（BTC）投資

在當前具有挑戰性的經濟狀況中，Atai Life Sciences在其金融戰略中選擇了比特幣投資。

Amid the current challenging economic condition termed as biotech winter, Atai Life Sciences has announced Bitcoin Investment in its financial strategy. The company, known for using psychedelics like DMT and MDMA in mental health treatment, has decided to invest $5 million in Bitcoin.

在目前被稱為生物技術冬季的挑戰性經濟狀況中，Atai Life Sciences宣布了比特幣投資其金融戰略。該公司以在心理健康治療中使用DMT和MDMA等迷幻藥而聞名，已決定向比特幣投資500萬美元。

Founder and chairman Christian Angermayer explains this decision in a detailed Substack post. He highlights the huge financial demands of drug development, which takes more than a decade to secure regulatory approvals. High inflation and rising interest rates put pressure on companies to adopt robust strategies to sustain daily operations.

創始人兼董事長克里斯蒂安·安吉爾默（Christian Angermayer）在詳細的替代帖子中解釋了這一決定。他強調了藥物開發的巨大財務需求，這需要十多年的時間才能獲得監管部門的批准。高通貨膨脹和利率上升給公司帶來壓力，要求公司採取強大的策略來維持日常運營。

Recent data and a TechCrunch report highlight how many biotech startups struggle with securing sufficient funds. Investors and experienced industry analysts observe these emerging trends and fully realize the harsh competitive realities in the biotech domain. Atai Life Sciences is actively exploring unconventional financial options and selecting Bitcoin to counter inflation risks effectively. The company is addressing traditional cash reserve inefficiencies by introducing digital currency solutions for improved performance. This strategic move aims to preserve capital and boost asset value during times of severe financial precarity.

最近的數據和TechCrunch報告強調了有多少生物技術初創公司在獲得足夠的資金方面努力。投資者和經驗豐富的行業分析師觀察了這些新興趨勢，並充分意識到了生物技術領域的嚴峻競爭現實。 Atai Life Sciences正在積極探索非常規財務選擇，並選擇比特幣有效地應對通貨膨脹風險。該公司通過引入數字貨幣解決方案以提高性能來解決傳統現金儲備效率低下。這一戰略舉動旨在在嚴重的財務pre義時期維護資本並提高資產價值。

(Related: Atai Among Biotech Firms Investing In Bitcoin As Startups Face Funding Crisis)

（相關：在生物技術公司投資比特幣時，ATAI面臨資金危機）

Atai Life Sciences has made a noteworthy move that reflects a broader trend of public medical companies increasingly engaging with Bitcoin. Quantum BioPharma is allocating a total of $3.5 million to cryptocurrencies, beginning with a $1 million investment. Semler Scientific is making a substantial commitment by purchasing 3,192 Bitcoins for $280.4 million to bolster its holdings. The companies are evidently keen on using cryptocurrencies to mitigate financial instability and economic challenges. These investments highlight a strategic shift, encouraging public medical firms to engage with digital currencies more actively.

Atai Life Sciences做出了一個值得注意的舉動，這反映了公共醫療公司越來越多地與比特幣互動的更廣泛趨勢。從100萬美元的投資開始，量子生物製藥總共將350萬美元分配給加密貨幣。 Semler Scientific通過以2.804億美元的價格購買3,192個比特幣來促進其持股，這做出了重大承諾。這些公司顯然熱衷於使用加密貨幣來減輕金融不穩定和經濟挑戰。這些投資強調了戰略轉變，鼓勵公共醫療公司更積極地與數字貨幣互動。

Firms such as Hoth Therapeutics, Acurx Pharmaceuticals, and Enlivex Therapeutics are each investing $1 million in Bitcoin. These companies are adopting diversified financial strategies to shield them from a worsening economic downturn. They are converting portions of their treasury into Bitcoin to safeguard against inflation and enhance financial returns. Investors recognize these proactive moves as strategies that strengthen financial portfolios during uncertain market conditions. These companies are embracing digital currencies to safeguard their assets and strive for better returns in a volatile market.

Hoth Therapeutics，Acurx Pharmaceuticals和Enlivex Therapeutics等公司都向比特幣投資了100萬美元。這些公司正在採用多元化的財務戰略，以保護他們免受經濟不景氣的惡化。他們正在將財政部的一部分轉換為比特幣，以保護通貨膨脹並提高財務回報。投資者認為這些積極主動的舉動是在不確定的市場條件下加強金融投資組合的策略。這些公司正在採用數字貨幣來維護其資產，並努力在動蕩的市場中獲得更好的回報。

Christian Angermayer, the founder and chairman of Atai Life Sciences, has disclosed that the company is investing in Bitcoin to hedge against inflation risks and diversify its short-term assets. Atai’s Bitcoin strategy is designed to counter market volatility and maintain a balanced portfolio. They are arranging portfolios with US dollars, short-term securities, and stocks to minimize market risk. This approach ensures the company’s financial runway through 2027 and supports biotech funding endeavors. The team is adeptly navigating market fluctuations and funding complexities with strategic investments and agile decision-making. Atai is committed to robust financial planning while pursuing innovative investment opportunities every day.

ATAI Life Sciences的創始人兼董事長Christian Angermayer透露，該公司正在投資比特幣，以抵制通貨膨脹風險並使其短期資產多樣化。 Atai的比特幣戰略旨在抵消市場波動和保持平衡的投資組合。他們正在用美元，短期證券和股票安排投資組合，以最大程度地降低市場風險。這種方法可確保公司在2027年的金融跑道，並支持生物技術資金努力。該團隊通過戰略投資和敏捷的決策來熟練地導航市場波動和資金復雜性。 Atai致力於強大的財務計劃，同時每天尋求創新的投資機會。

Atai Life Sciences saw a modest share price increase after announcing its strategic Bitcoin investment. They keep share prices below the 2021 post-IPO peak as the market responds. Atai ranks as the 52nd largest public company Bitcoin holder by these strategic financial moves.

Atai Life Sciences在宣布其戰略性比特幣投資後，股價略有上漲。隨著市場的回應，他們將股票價格保持在2021年IPO峰的低於2021年。通過這些戰略財務轉會，Atai是第52大的上市公司比特幣持有人。

Investors show cautious optimism as they integrate cryptocurrencies into corporate treasuries across industries. Biopharma companies demand financial stability for long-term research and strict regulatory compliance. This management drives innovative strategies that strengthen investor confidence and support dynamic growth plans.

投資者將加密貨幣納入整個行業的公司國庫時表現出謹慎的樂觀情緒。生物製藥公司需要財務穩定性，以進行長期研究和嚴格的監管合規性。這種管理推動了創新策略，從而增強了投資者的信心並支持動態增長計劃。

Atai Life Sciences and other medical firms are now adopting the Bitcoin strategy to handle financial challenges during economic downturns. These companies highlight a fundamental shift in managing finances while enduring prolonged economic stress and uncertainty. Biopharmaceutical firms are continually confronting escalating operational costs and slow regulatory processes. Cryptocurrencies now provide companies with novel ways to manage assets and hedge against fiscal instability. These digital tools empower firms to enhance financial strategies and navigate economic turbulence effectively. Firms are quickly adapting to these solutions as they seek robust financial resilience during market challenges.

ATAI生命科學和其他醫療公司現在正在採用比特幣戰略來應對經濟低迷期間的財務挑戰。這些公司重點介紹了管理財務的根本轉變，同時忍受了長期的經濟壓力和不確定性。生物製藥公司正在不斷面對不斷升級的運營成本和緩慢的監管過程。現在，加密貨幣為公司提供了管理資產和對沖財政不穩定的新方法。這些數字工具授權公司有效地增強財務戰略並有效地導航經濟動盪。當公司在市場挑戰期間尋求強大的財務彈性時，公司正在迅速適應這些解決方案。